oral formulation

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Bio & Pharma Kobiolabs gets US patent for oral obesity drug candidate

Kobiolabs Co., a South Korean microbiome-based new drug development company, announced on Wednesday that it has a patent for Roseburia intestinalis ...

Bio & Pharma Inventage Lab, Yuhan to co-work for obesity treatment

South Korea’s Inventage Lab Inc. announced on Friday that it has signed a joint development agreement with Yuhan Corp. for a long-acting inj...

Bio & Pharma LG Chem out-licenses obesity drug candidate to US firm

LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...

Beauty & Cosmetics Cosmax targets Thailand with K-beauty cosmetic formulations

Cosmax Inc., South Korea's largest cosmetics manufacturer that specializes in original design manufacturing (ODM), announced on Monday that it is ac...

Bio & Pharma HLB gets global rights to Chinese liver cancer drug

South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...

Bio & Pharma AriBio to sell dementia drug AR1001 in China with partner

South Korea's clinical-stage biotech company AriBio Co. on Wednesday said it signed a memorandum of understanding on strategic cooperation with Chin...

Bio & Pharma AriBio applies for Phase 3 clinical trials in China for oral dementia drug

South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...

Bio & Pharma Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA

Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean ph...

Bio & Pharma Celltrion to develop Humira biosimilar oral medication with US firm

South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...

Bio & Pharma Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

Bio & Pharma Celltrion develops oral antibody drug with US bio company

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

Bio & Pharma Daewoong, Onchorus to undertake research on mRNA anticancer drugs

Daewoong Pharmaceutical said on Thursday that it has signed a joint R&D and commercialization agreement with America's biopharmaceutical venture...

Bio & Pharma S.Korea's Alteogen signs $145 million tech export deal with Swiss company

South Korea's bio company Alteogen Inc. on Friday said it signed its fourth technology export contract since its 2018 development of the human recom...

Bio & Pharma S.Korea's Medicox boosts unit for oral insulin, medical cannabis

South Korea's Medicox Co. on Wednesday said it will raise 40 billion won ($32 million) to boost its unit for oral insulin and cannabidiol (CBD).The ...

Bio & Pharma Helixmith acquires US patent on new freeze-dried formulation

South Korea's biotech company Helixmith Co. said Wednesday it has developed and patented a new freeze-dried formulation for Engensis (VM202), a non-...

Bio & Pharma Korean bio firms look to pills, patches for people who fear needles

Getting shots of a drug or vaccine over a long period is not easy for many people.That's probably why global biopharmaceutical companies and biotech...